Shanghai Bio-heart Biological Technology Co Ltd
02185
Company Profile
Business description
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.
Contact
No.590 Ruiqing Road
Room 302, 3rd Floor, Building 4 & Building 6
East Zhangjiang Hi-Tech Park
Pudong New Area
Shanghai
CHNT: +86 2168798511
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
stocks
2 undervalued ASX shares report
These two ASX shares are trading at a discount to our fair value.
stocks
Turmoil at WiseTech
Board members step down over differences on the role of former CEO Richard White.
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,503.20 | 56.90 | -0.66% |
| CAC 40 | 8,090.99 | 63.52 | -0.78% |
| DAX 40 | 22,425.93 | 138.37 | 0.62% |
| Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
| FTSE 100 | 8,658.98 | 0.39 | -0.00% |
| HKSE | 23,184.55 | 157.06 | -0.67% |
| NASDAQ | 19,286.93 | 237.08 | -1.21% |
| Nikkei 225 | 38,364.37 | 412.57 | -1.06% |
| NZX 50 Index | 12,363.34 | 168.38 | -1.34% |
| S&P 500 | 5,983.25 | 29.88 | -0.50% |
| S&P/ASX 200 | 8,255.70 | 52.50 | -0.63% |
| SSE Composite Index | 3,368.52 | 4.50 | -0.13% |